Delphi consensus on the diagnosis and treatment of patients with short stature in Spain: GROW-SENS study; 34791604
Resumen: Purpose: To identify consensus aspects related to the diagnosis, monitoring, and treatment of short stature in children to promote excellence in clinical practice. Methods: Delphi consensus organised in three rounds completed by 36 paediatric endocrinologists. The questionnaire consisted of 26 topics grouped into: (1) diagnosis; (2) monitoring of the small-for-gestational-age (SGA) patient; (3) growth hormone treatment; and (4) treatment adherence. For each topic, different questions or statements were proposed. Results: After three rounds, consensus was reached on 16 of the 26 topics. The main agreements were: (1) diagnosis tests considered as a priority in Primary Care were complete blood count, biochemistry, thyroid profile, and coeliac disease screening. The genetic test with the greatest diagnostic value was karyotyping. The main criterion for initiating a diagnostic study was prediction of adult stature 2 standard deviations below the target height; (2) the main criterion for initiating treatment in SGA patients was the previous growth pattern and mean parental stature; (3) the main criterion for response to treatment was a significant increase in growth velocity and the most important parameter to monitor adverse events was carbohydrate metabolism; (4) the main attitude towards non-responding patients is to check their treatment adherence with recording devices. The most important criterion for choosing the delivery device was its technical characteristics. Conclusions: This study shows the different degrees of consensus among paediatric endocrinologists in Spain concerning the diagnosis and treatment of short stature, which enables the identification of research areas to optimise the management of such patients. © 2021, The Author(s).
Idioma: Inglés
DOI: 10.1007/s40618-021-01696-0
Año: 2022
Publicado en: Journal of endocrinological investigation 45 (2022), 887-897
ISSN: 0391-4097

Factor impacto JCR: 5.4 (2022)
Categ. JCR: ENDOCRINOLOGY & METABOLISM rank: 34 / 144 = 0.236 (2022) - Q1 - T1
Factor impacto CITESCORE: 8.1 - Medicine (Q1) - Biochemistry, Genetics and Molecular Biology (Q1)

Factor impacto SCIMAGO: 0.996 - Endocrinology, Diabetes and Metabolism (Q2) - Endocrinology (Q2)

Tipo y forma: Article (Published version)
Área (Departamento): Área Pediatría (Dpto. Microb.Ped.Radio.Sal.Pú.)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.


Exportado de SIDERAL (2025-02-21-09:52:50)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Pediatría



 Record created 2025-02-21, last modified 2025-02-21


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)